Hematology/Oncology Clinics of North America This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Advances in the Surgical Management of Esophageal Cancer
Radical esophagectomy with two or three-field lymphadenectomy remains the mainstay of curative treatment for localized esophageal cancer, often in combination with systemic chemotherapy and/or radiotherapy. In this article, we describe notable advances in the surgical management of esophageal cancer over the past decade that have led to an improvement in both surgical and oncologic outcomes. In addition, we discuss new approaches to surgical management currently under investigation that have the potential to offer further benefits to appropriately selected patients. These incremental breakthroughs primarily include advance...
Source: Hematology/Oncology Clinics of North America - April 5, 2024 Category: Cancer & Oncology Authors: Smita Sihag Source Type: research

Advances in the Imaging of Esophageal and Gastroesophageal Junction Malignancies
Accurate imaging is key for the diagnosis and treatment of esophageal and gastroesophageal junction cancers . Current imaging modalities, such as computed tomography (CT) and 18F-FDG (2-deoxy-2-[18F]fluoro-D-glucose) positron emission tomography (PET)/CT, have limitations in accurately staging these cancers. MRI shows promise for T staging and residual disease assessment. Novel PET tracers, like FAPI, FLT, and hypoxia markers, offer potential improvements in diagnostic accuracy. 18F-FDG PET/MRI combines metabolic and anatomic information, enhancing disease evaluation. Radiomics and artificial intelligence hold promise for ...
Source: Hematology/Oncology Clinics of North America - April 3, 2024 Category: Cancer & Oncology Authors: Lisa Ruby, Vetri Sudar Jayaprakasam, Maria Clara Fernandes, Viktoriya Paroder Source Type: research

Advances in Systemic Therapy in Pancreatic Cancer
Substantial progress has been made toward understanding biology and developing new therapies for pancreatic ductal adenocarcinoma (PDAC). In this review, new insights from genomic profiling, as well as implications for treatment and prognosis, are discussed. New standards of care approaches with a focus on drug therapies are discussed for the treatment of resectable and advanced PDAC. The role of targeted and immune therapies remains limited; cohorts likely to benefit from these approaches are discussed. Promising, preliminary results regarding experimental therapies are reviewed. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - April 3, 2024 Category: Cancer & Oncology Authors: Kenneth H. Yu Source Type: research

Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers
The Trastuzumab for Gastric Cancer (ToGA) trial marked a pivotal moment in the adoption of trastuzumab for treating advanced human epidermal growth factor receptor 2 (HER2)-positive esophagogastric (EG) cancer. The KEYNOTE-811 trial brought to light the synergistic effect of immune modulation and HER2 targeting. Additionally, the emergence of trastuzumab deruxtecan (T-DXd) highlighted the potential of new pharmaceutical technologies to extend response, particularly for patients who have advanced beyond initial HER2-targeted therapies. This review aims to navigate through both the successes and challenges encountered histor...
Source: Hematology/Oncology Clinics of North America - March 24, 2024 Category: Cancer & Oncology Authors: Jaeyop Lee, Geoffrey Ku Source Type: research

Advances in Immunotherapy in Esophagogastric Cancer
Immune checkpoint inhibitors are rapidly transforming the care of patients with esophagogastric cancer. Particularly, anti-PD-1 therapy has demonstrated promising efficacy in metastatic and resectable disease. In this review, the authors discuss landmark clinical trials, highlight challenges and opportunities in this field, and propose potential directions for future work. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - March 15, 2024 Category: Cancer & Oncology Authors: Khalid Jazieh, Harry Yoon, Mojun Zhu Source Type: research

Esophagogastric Cancer
Radiation therapy is an effective treatment modality in the management of patients with esophageal cancer regardless of tumor location (proximal, middle, or distal esophagus) or histology (squamous cell vs adenocarcinoma). The addition of neoadjuvant CRT to surgery in patients who are surgical candidates has consistently shown a benefit in terms of locoregional recurrence, pathologic downstaging, and overall survival. For patients who are not surgical candidates, CRT has a role as definitive treatment. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - March 13, 2024 Category: Cancer & Oncology Authors: Leila T. Tchelebi, Karyn A. Goodman Source Type: research

Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2
Gastroesophageal cancers are highly diverse tumors in terms of their anatomic and molecular characteristics, making drug development challenging. Recent advancements in understanding the molecular profiles of these cancers have led to the identification of several new biomarkers. Ongoing clinical trials are investigating new targeted agents with promising results. CLDN18.2 has emerged as a biomarker with established activity of associated targeted therapies. Other targeted agents, such as bemarituzumab and DKN-01, are under active investigation. As new agents are incorporated into the treatment continuum, the questions of ...
Source: Hematology/Oncology Clinics of North America - March 13, 2024 Category: Cancer & Oncology Authors: Eric Mehlhaff, Devon Miller, Johnathan E. Ebben, Oleksii Dobrzhanskyi, Nataliya V. Uboha Source Type: research

Upper Gastrointestinal Cancers and the Role of Genetic Testing
Beyond the few established hereditary cancer syndromes with an upper gastrointestinal cancer component, there is increasing recognition of the contribution of novel pathogenic germline variants (gPVs) to upper gastrointestinal carcinogenesis. The detection of gPVs has potential implications for novel treatment approaches of the index cancer patient as well as long-term implications for surveillance and risk-reducing measures for cancer survivors and far-reaching implications for the patients ’ family. With widespread availability of multigene panel testing, new associations may be identified with germline-somatic integra...
Source: Hematology/Oncology Clinics of North America - March 7, 2024 Category: Cancer & Oncology Authors: Emily C. Harrold, Zsofia K. Stadler Source Type: research

The Role of Screening and Early Detection in Upper Gastrointestinal Cancers
Upper gastrointestinal cancers are among the leading causes of cancer deaths worldwide with exceptionally poor prognosis, which is largely attributable to frequently delayed diagnosis. Although effective screening is critical for early detection, the highly variable incidence of upper gastrointestinal cancers presents challenges, rendering universal screening programs suboptimal in most populations globally. Optimal strategies in regions of modest incidence, such as the United States, require a targeted approach, focused on high-risk individuals based on demographic, familial, and clinicopathologic risk factors. Assessment...
Source: Hematology/Oncology Clinics of North America - March 1, 2024 Category: Cancer & Oncology Authors: Jin Woo Yoo, Monika Laszkowska, Robin B. Mendelsohn Source Type: research

Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
A multimodality approach, which usually includes chemotherapy, surgery, and/or radiotherapy, is optimal for patients with localized pancreatic cancer. The timing and sequence of these interventions depend on anatomic resectability and the biological suitability of the tumor and the patient. Tumors with vascular involvement (ie, borderline resectable/locally advanced) require surgical reassessments after therapy and participation of surgeons familiar with advanced techniques. When indicated, venous reconstruction should be offered as standard of care because it has acceptable morbidity. Morbidity and mortality of pancreas s...
Source: Hematology/Oncology Clinics of North America - February 29, 2024 Category: Cancer & Oncology Authors: Mengyuan Liu, Alice C. Wei Source Type: research

Immunotherapy
Biliary tract cancers continue to increase in incidence and have a high mortality rate. Most of the patients present with advanced-stage disease. The discovery of targetable genomic alterations addressing IDH, FGFR, HER2, BRAFV600  E, and others has led to the identification and validation of novel therapies in biliary cancer. Recent advances demonstrating an improved outcome with the addition of immune checkpoint inhibitors to chemotherapy have established a new first-line care standard. In case of contraindications to the use of checkpoint inhibitors and the absence of targetable alterations, chemotherapy remains to be ...
Source: Hematology/Oncology Clinics of North America - February 28, 2024 Category: Cancer & Oncology Authors: Layal Al Mahmasani, James J. Harding, Ghassan Abou-Alfa Source Type: research

New Developments in Myeloma
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - February 27, 2024 Category: Cancer & Oncology Authors: Peter Leif Bergsagel Source Type: research

Copyright
ELSEVIER (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - February 27, 2024 Category: Cancer & Oncology Source Type: research

Contributors
GEORGE P. CANELLOS, MD (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - February 27, 2024 Category: Cancer & Oncology Source Type: research

Contents
Peter Leif Bergsagel (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - February 27, 2024 Category: Cancer & Oncology Source Type: research